The average P/S ratio for NAMS's competitors is 38.35, providing a benchmark for relative valuation. NewAmsterdam Pharma Company NV Corp (NAMS) exhibits a P/S ratio of 141.88, which is 269.97% above the industry average. Given its robust revenue growth of 112.56%, this premium appears sustainable.